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Background: Curcumin exhibits anti-diabetic activities, induces heme-oxygenase-1 (HO-1) and is an inhibitor of
transcriptional co-activator p300. A novel water soluble curcumin derivative (NCD) has been developed to
overcome low invivo bioavailability of curcumin. We evaluated the effect of the NCD on signaling mechanisms
involved in cardiomyocyte hypertrophy and studied whether its action is mediated via inducible HO-1.
Materials and methods: Rats were divided into controls, controls receiving NCD, diabetic, diabetic receiving NCD,
diabetic receiving pure curcumin, diabetic receiving HO inhibitor, zinc protoporphyrin IX (ZnPP IX) and diabetic
receiving NCD and ZnPP IX. NCD and curcumin were given orally. After 45 days, cardiac physiologic parameters,
plasma glucose, insulin, glycated hemoglobin (GHb), HO-1 gene expression and HO activity in pancreas and cardiac
tissues were assessed. Gene expression of p300, atrial natriuretic peptide (ANP) and myocyte enhancer factor 2
(MEF2A and MEF2C) were studied.
Results: NCD and curcumin decreased plasma glucose, GHb and increased insulin levels significantly in diabetic
rats. This action may be partially mediated by induction of HO-1 gene. HO-1 gene expression and HO activity were
significantly increased in diabetic heart and pancreas. Diabetes upregulated the expression of ANP, MEF2A, MEF2C
and p300. NCD and curcumin prevented diabetes-induced upregulation of these parameters and improved left
ventricular function. The effect of the NCD was better than the same dose of curcumin.
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By the year 2025, 300 million people worldwide will have
diabetes mellitus (DM) [1]. There is evidence that com-
plications related to DM are associated with increased
oxidative stress induced by generation of free radicals
[2]. Antioxidant treatment which suppresses apoptosis
of β-cells was shown to preserve β-cell function in
diabetic mice [3].
Curcumin (1, 7 bis (4 hydroxy-3 methoxy phenol)-1, 6
heptadiene-3, 5 dione) is a yellow phenolic compound
present in turmeric (Curcuma longa) a widely used spice* Correspondence: talaatabdaziz@yahoo.co.uk
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reproduction in any medium, provided the orin Indian cuisine. Curcumin has a number of biological
applications along with a significant antioxidant activity
both in vivo and in vitro [4]. Although the mechanisms
involved are poorly understood, curcumin can protect
against oxidative stress and induce heme oxygenase-1
(HO-1) expression, which exerts cytoprotective effects in
mouse pancreatic beta-cells. These effects were mediated
through the activation of Nrf2 by a PI3-kinase/Akt-
mediated pathway in mouse β cells [5].
Curcumin (turmeric) exhibits therapeutic actions in
DM. Abdel Aziz et al [6] reported that insulin secretion,
HO-1 gene expression and HO activity were significantly
increased when rat isolated islets of Langerhans were
incubated in curcumin. This increase in insulin secretion. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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HO inhibitor, stannous mesoporphyrin (SnMP) suggesting
that the action of curcumin on insulin secretion from iso-
lated islets may be, in part, mediated through increased
HO-1 gene expression.
Cardiomyocte hypertrophy as well as subsequent
apoptosis and focal myocardial fibrosis are structural
hallmarks of diabetic cardiomyopathy and functionally
manifest as defective cardiac contractility [7]. Oxidative
stress, due to glucose-mediated increase in mitochon-
drial superoxide production, has been suggested to be of
importance in several chronic diabetic complications,
including cardiomyopathy [8].
DM may lead to myocardial hypertrophy in association
with an upregulation of vasoactive factors such as
endothelin-1 and activation of redox-sensitive transcrip-
tion factors such as NF-κB and activating protein-1
(AP-1) [8,9]. Transcription factors are regulated by
transcriptional coactivators, especially those containing
histone acetyltransferase (HAT) activity; p300 is the
best known of such proteins [10]. Furthermore, p300
plays an important role in regulating both myocyte
enhancer factor 2 (MEF2) and GATA-binding protein 4
[11]. MEF2 (MEF2A and MEF2C) is an important tran-
scription factor in myocyte hypertrophy and is involved
in mediating the hypertrophic action of glucose on
cardiomyocytes [12]. MEF2 is associated with class II
histone deacetylases (HDACs). Translocation of HDAC
to the cytoplasm frees up MEF2, which allows for its
association with HATs, like p300, leading to the tran-
scription of effector genes [12,13].
Curcumin has been reported to be an inhibitor of p300-
HAT [14] therefore; it may possess an effect in the preven-
tion of cardiac hypertrophy and heart failure [15]. Because
of the poor bioavailability of pure curcumin, a new
water soluble curcumin derivative (Patent pending
PCT/EG2010/000008) was used in this study.
The aim of the present work is to evaluate the effect
of a novel water soluble curcumin derivative (3%
curcumin content) on signaling mechanisms involved in
cardiomyocyte hypertrophy and dysfunction in myocar-
dial contractility in DM and to study whether its action
is mediated via inducible HO-1.Materials and methods
This study was performed at the Unit of Biochemistry
and Molecular Biology at The Medical Biochemistry
Department, Faculty of Medicine, Cairo University,
Egypt. Curcumin protein conjugate was presented free
of charge to the participating researchers as a personal
non-profit scientific donation to help advancement of
cooperation in national medical research. The novel
derivative, with 3.0% curcumin content is registeredas international patent protected by the rights of
“The Patent Cooperation Treaty” and are the personal
property of their inventors (Patent pending PCT/
EG2010/000008 Published Patent Pending, WO 2011/
100984) [16].
Experimental animals
The experiments were performed on 140 adult rats
weighing 150 to 200 g obtained from an inbred colony
(Curl: HEL1) at the Kasr Al-Aini animal experimental
unit, Faculty of Medicine, Cairo University. These ani-
mals were kept in an environment with controlled
temperature (25°C), humidity (45-75%) and 12:12 h
light:dark cycle. All animals were fed ad libitum and had
free access to water. The 140 rats were divided into 4
groups (Table 1). All the ethical protocols for animal
treatment were followed and supervised by the animal
facilities, Faculty of Medicine, Cairo University. All ani-
mal experiments received approval from the Institutional
Animal Ethics Committee.
– The animals were acclimatized for 1 week before
initiation of the experiment.
– DM was induced in 100 rats by a single i.p. injection
of streptozotocin (STZ) dissolved in 0.1 M sodium
citrate buffer, pH 4.5, at a dose of 50 mg/kg.
– After 72 h, fasting blood glucose levels were
monitored and animals with blood glucose levels
>200 mg/dL were considered diabetic and were
distributed into the previously mentioned groups.
– Age-matched control rats were injected with an
equal volume of vehicle (sodium citrate buffer).
At the planned time of sacrifice (after 45 days):
 Ninety nine rats remained and 41 rats died with a
mortality rate of (29.3%)
 Six rats from each group were used for assessment
of physiological parameters: left ventricular
developed pressure, left ventricular delta pressure/
delta time (contractility index), systolic blood
pressure and heart rate.
 Fasting blood samples were withdrawn from the
retro-orbital vein of the remaining rats to assess
plasma insulin, plasma glucose and glycated Hb
(GHb). This was followed by sacrifice of the animals
by cervical dislocation. The pancreas and heart were
excised for assessment of:– HO enzyme activity
– HO-1 gene expression by real time PCR.
– Gene expression of p300 and molecular markers of
cardiac hypertrophy such as ANP, MEF2A, and
MEF2C by real time PCR
Table 1 Classification of studied groups
Groups
Group 1(a) Control: 20 rats.
Group 1(b) Pathological control: Twenty streptozotocin-induced diabetic rats
Group 2(a) Twenty control rats that received a daily oral dose of the water soluble curcumin derivative (NCD) at a dose of 20 mg/kg body
weight for 45 days.
Group 2(b) Twenty diabetic rats that received a daily oral dose of the NCD at a dose of 20 mg/kg body weight for 45 days after the induction
of DM.
Group 3(a) Twenty diabetic rats that received a daily oral dose of the NCD at a dose of 20 mg/kg body weight for 45 days after induction of
DM and a weekly intraperitoneal (i.p.) dose of HO-1 inhibitor, ZnPP IX (10 μmol/Kg dissolved in sodium hydroxide 0.1 N and sodium
chloride 0.9% and pH adjusted to pH 7.4) for 6 weeks.
Group 3(b) Twenty diabetic rats that received a weekly i.p. dose of HO-1 inhibitor, ZnPP IX (10 μmol/Kg dissolved in sodium hydroxide 0.1 N
and sodium chloride 0.9% and pH adjusted to pH 7.4) for 6 weeks.
Group 4 Twenty diabetic rats that received a daily oral dose of pure curcumin at a dose of 20 mg/kg body weight for 45 days after
induction of DM.
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The cardiovascular system was assessed using a
Langendorff apparatus. Hearts were rapidly excised and
immersed in ice-cold Krebs-Henseleit solution containing
heparin (5000 u) at ambient temperature (25°C), then
mounted on the aortic cannula and subsequently perfused
according to the Langendorff technique with Krebs-
Henseleit medium at a hydrostatic pressure of 55 cm H2O
and bubbled with a mixture of 95% O2 and 5% CO2. The
time between extraction of the hearts and their attach-
ment to the Langendorff apparatus did not exceed 2 min.
The Krebs-Henseleit solution was prepared according
to the following concentrations in (g): 6.926 NaCl, 2.1
NaHCO3, 0.16 KH2PO4, 0.298 KCl, 0.294 MgSO4, 0.264
CaCl2 and 1.982 glucose in 1 L distilled water. A roller
pump delivered the medium (flow = 15 mL/min) to an
8 μm-pore – size 47-mm-diameter filter, a membrane oxy-
genator, a pre-heater, and the cannula. The temperature of
the heart and of the perfusion medium was maintained at
37°C by an external water bath. A latex balloon filled with
saline was introduced into the left ventricle and was
connected to a pressure transducer to monitor performance.
We measured the intraventricular balloon volume needed
to increase end diastolic pressure from 0 to 10-15 mmHg;
afterwards the balloon volume was kept constant.
Mechanical performances of the left ventricle of the
heart was determined by the systolic pressure, the heart
rate and the peak rate of maximum left ventricular pres-
sure rise (dp/dt) which is a good index of contractility.
These mechanical performance parameters were moni-
tored during the experiment by a balloon inserted into
the left ventricle and connected to a polygraph apparatus
(San-ei Instruments, Ltd.) The developed pressure was
calculated (systolic pressure – diastolic pressure) [17].
Plasma glucose estimation
Blood was collected from the retro-orbital vein into tubes
containing fluoride. Plasma samples were separated bycentrifugation at 3000 rpm for 10 min. Plasma glucose
was measured by the glucose oxidase method [18] using a
commercially available kit (Diamond, Egypt).
Plasma insulin estimation
Plasma insulin was assayed by a commercially available
Enzyme-linked immunosorbent assay (ELISA) kit sup-
plied by DRG Diagnostics (GmbH, Germany) [19].
Glycated hemoglobin estimation
Whole blood was collected by venipuncture from the
retro orbital vein into tubes containing EDTA as anti-
coagulant. Glycated hemoglobin was assayed by a com-
mercially available kit supplied by Stanbio [20].
HO activity assay
Pancreatic and cardiac tissues were homogenized with
2.5 volume Tris–HCl buffer (10 mmol/L, pH 7.6)
containing 250 mmol/L sucrose and 0.4 mmol/L
phenylmethylsulfonyl fluoride. The homogenate was
centrifuged at 800 g for 10 min and then at 13 500 g for
20 min to produce a mitochondrial pellet. The super-
natant was withdrawn. The protein content was deter-
mined by the method of Lowry et al [21]. The activity of
HO in the supernatant was determined as previously
described [22].
RNA extraction and reverse transcription
– Total RNA was extracted from pancreatic and
cardiac tissues by using SV Total RNA Isolation
System supplied by Promega (Promega, Madison,
WI, USA) according to the manufacturer’s protocol.
Extracted RNA was quantified by
spectrophotometer at 260 nm
– The extracted RNA was reversed transcribed into
cDNA using Reverse Transcription System kit
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5 μg of total RNA extracted with 1 μl (20 pmol)
antisense primer and 0.8 μl superscript AMV
reverse transcriptase for 60 min at 37°C.Real-time quantitative analyses for p300, ANP, MEF2A,
MEF2C and HO-1 gene expression
cDNA was generated from 5 μg of total RNA extracted
with 1 μl (20 pmol) antisense primer and 0.8 μl super-
script AMV reverse transcriptase for 60 min at 37°C.Real-time quantitative analyses
The relative abundance of mRNA species was assessed
using the SYBRW Green method on an ABI prism 7500
sequence detector system (Applied Biosystems, Foster
City, CA). PCR primers were designed with Gene Run-
ner Software (Hasting Software, Inc., Hasting, NY)
from RNA sequences from GenBank (Table 2). All pri-
mer sets had a calculated annealing temperature of 60°.
Quantitative RT-PCR was performed in duplicate in a
25 μl reaction volume consisting of 2X SYBR Green
PCR Master Mix (Applied Biosystems), 900 nM of each
primer and 2-3 μl of cDNA. Amplification conditions
were 2 min at 50°C, 10 min at 95°C and 40 cycles of de-
naturation for 15 s and annealing/extension at 60° for
10 min. Data from real-time assays were calculated
using the v1 · 7 Sequence Detection Software from PE
Biosystems (Foster City, CA). Relative expression of
p300, ANP, MEF2A, MEF2C and HO-1 was calculated
using the comparative Ct method as previously de-
scribed. All values were normalized to the beta actin
genes and reported as fold change.ble 2 Oligonucleotide primers sequence used for real-
me PCR
ne Primer sequence
00 Forward primer: 50- GCTGCGCTGGAGGAAGCCAA--30
W_047658.2 Reverse primer: 50-TTCTCGCAGCGCGCCTGAAA-30
P Forward primer: 50- GCCTGAAGGGTTTTGGGCAGCA-30
W_047727.1 Reverse primer: 50-ACCGTCACAGCCCAAGCGAC-30
EF2A Forward primer: 50-ACAACCTCTTGCCACGCCCG-30
W_001084766.1 Reverse primer: 50-AGGGGAGCGCCCCATTTCCT-30
EF2C Forward primer: 50- GATGGGCATGACAGACGAGAAG
GGA-30
C_005101.3 Reverse primer: 50-GCCAATGACTGGGCCGACTGG-30
O-1 Forward primer: 50-GAGCGCCCACAGCTCGACAG-30
2722.1 Reverse primer: 50-GTGGGCCACCAGCAGCTCAG-30
Actin Forward primer: 50-CCTTCCTGGGCATGGAGTCCT-30
iSTS: 270185 Reverse primer: 50- GGAGCAATGATCTTGATCTTC-30Statistical analysis
ANOVA test was used to test the significance between
groups. Post hoc test was used to test the difference
between each 2 groups using “Statistica version 8.0”
(Statsoft Inc., USA) software. Data were presented as
mean ± standard deviation (SD). The differences between




Diabetic rats showed a reduction in contractility of dia-
betic hearts represented by lower LV dp/dt and lower
LVDP Diabetic hearts also exhibited reduced heart rate
and increased systolic blood pressure.
In diabetic rats receiving the NCD or pure curcumin,
left ventricular function was improved as indicated by
increased heart rate, LVDP, LV dp/dt and decreased sys-
tolic blood pressure when compared with diabetic rats.
Diabetic rats receiving pure curcumin showed no sig-
nificant difference in left ventricular function compared
with the diabetic group receiving the NCD. Also, feeding
NCD did not affect these parameters in the control
group (Table 3).
Blood glucose, insulin levels and glycated hemoglobin
levels
There was a significant increase (p < 0.001) in the mean
plasma glucose level in the diabetic group compared
with the control group. On the other hand the mean
plasma glucose level in the control group showed no sig-
nificant difference (p > 0.05) compared with the control
group receiving the oral NCD. Oral NCD supplementa-
tion to diabetic rats resulted in a significant decrease
(p < 0.001) in the mean plasma glucose level compared
with the diabetic group. Also, pure curcumin supplemen-
tation to diabetic rats resulted in a significant decrease in
plasma glucose level (p < 0.001) compared with the dia-
betic group, whereas, it showed no significant difference
(p > 0.05) compared with diabetic group receiving the oral
NCD derivative (Table 4).
A significant decrease (p < 0.001) in the mean plasma
insulin level in the diabetic group compared with the
control group was detected. In addition, there was a sig-
nificant increase (p < 0.01) in the mean plasma insulin
level in the control group receiving the oral NCD com-
pared with the control group. Oral NCD supplementation
to diabetic rats resulted in a significant increase (p < 0.05)
in the mean plasma insulin level compared with the dia-
betic group (Table 4).
A significant increase (p < 0.05) in the mean fasting
plasma insulin level in the diabetic group receiving pure
curcumin compared with the diabetic group was
detected. Whereas, it showed no significant difference








NCD (n = 6)
Diabetic + pure
curcumin (n = 6)
Diabetic +
ZnPP (n = 6)
Diabetic + ZnPP +
NCD (n = 6)
Heart rate (beats/min) 166(a) ± 7 173(a) ± 6 122(b) ± 5 149©(d) ± 9 139(d) ± 6 118(e)(b) ± 6 140(f)(d) ± 5
Systolic Blood
pressure (mmHg)
118(a) ± 8 121(a) ± 8 145(b) ± 7 128(a)(d) ± 8 130(a)(d) ± 7 147(e)(b) ± 6 130(a)(f)(d) ± 05
LVDP (mmHg) 92(a) ± 5.3 93.3(a) ± 4.7 59(b) ± 6.0 75©(d) ± 4.5 70.6(d) ± 5.3 57(e)(b) ± 4.6 73(f)(d) ± 4.1
LV dp/dt (mmHg/sec) 139(a) ± 7.4 137.6(a) ± 7.2 101.2(b) ± 9.4 134.3(a) ± 5.2 133(a)(d) ± 5.2 94.3(b)(e) ± 8.6 128.6(a)(f) ± 8.5
LV dp/dt: left ventricular delta pressure/delta time (contractility index).
LVDP: Left ventricular developed pressure.
Groups that have similar letters are not significant while groups having different letters differ significantly (p < 0.05).
Results are presented as mean ± SD.
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the oral NCD (Table 4).
There was a significant increase (p < 0.001) in the mean
GHb level in the diabetic group compared with the con-
trol group. Diabetic rats supplemented with the NCD or
pure curcumin showed a modest but significantly lower
(p < 0.01) blood GHb level compared with the diabetic
group. But, their levels were still higher than the control
group. Whereas, no significant difference (p > 0.05) was
detected between diabetic rats receiving the NCD or pure
curcumin (Table 4).HO activity in heart and pancreas
There was a significant increase (p < 0.001) in the mean
HO activity in the pancreas and heart of diabetic rats
compared with the corresponding control groups.
NCD supplementation to the control rats significantly
increased the HO-1 expression in the pancreas (p < 0.01)
and heart (p < 0.001) compared with the corresponding
control groups. In addition, NCD supplementation to the
diabetic rats significantly increased (p < 0.001) HO-activity
in the pancreas and heart compared with the correspond-
ing control and diabetic groups (Table 5).
A significant increase (p < 0.001) in the HO activity in
the pancreas and the heart was detected in diabetic rats
receiving pure curcumin when compared with diabetic
rats. Pure curcumin supplementation showed a signifi-
cant decrease (p < 0.001) in the pancreas and heart com-
pared with the diabetic group receiving the oral NCD









Plasma glucose (mg/dL) 92 ± 6.9 91 ± 5.9 307* ± 31.4 183
Plasma insulin (μg/L) 1.10 ± 0.19 1.58*§ ± 0.36 0.47* ± 0.18 0.80
Glycated hemoglobin (%) 5.4 ± 0.7 5.5 ± 0.7 13.0* ± 1.0 11.
Results are presented as mean ± SD.
*Values differ significantly from control (p < 0.05). #Values differ significantly from D
§Values differ significantly from diabetic (p < 0.05). • Values differ significantly fromHO-1 gene expression in heart and pancreas
There was a significant increase (p < 0.001) in mean HO-1
expression level in the pancreas (0.95 ± 0.04 HO-1/
β-actin) and heart (0.80 ± 0.06 HO-1/β-actin) of diabetic
rats compared with the corresponding control groups
(0.32 ± 0.02 HO-1/β-actin and 0.24 ± 0.02 HO-1/β-actin),
respectively.
NCD supplementation to the control rats signifi-
cantly increased (p < 0.001) HO-1 expression in the
pancreas (0.58 ± 0.04 HO-1/β-actin) and heart (0.55 ±
0.06 HO-1/β-actin) compared with the corresponding
control groups (0.32 ± 0.02 HO-1/β-actin and 0.24 ±
0.2 HO-1/β-actin), respectively.
In addition, NCD supplementation to the diabetic
rats significantly increased (p < 0.001) HO-1 expression
in the pancreas (1.86 ± 0.06 HO-1/β-actin), and heart
(1.37 ± 0.05 HO-1/β-actin) compared with the corre-
sponding control groups (0.32 ± 0.02 HO-1/β-actin and
0.24 ± 0.02 HO-1/β-actin) and corresponding diabetic
groups (0.95 ± 0.03 HO-1/β-actin and 0.80 ± 0.06 HO-1/β-
actin), respectively.
A significant increase (p < 0.001) in the HO-1 gene
expression in the pancreas (1.76 ± 0.03 HO-1/β-actin)
and the heart (1.23 ± 0.1 HO-1/β-actin) was detected in
diabetic rats receiving pure curcumin when compared
with diabetic rats (0.95 ± 0.03 HO-1/β-actin) and (0.95 ±
0.03 HO-1/β-actin), respectively. Whereas, pure curcumin
supplementation showed a significant decrease (p < 0.001)
compared with diabetic group receiving the oral NCD de-
rivative in the pancreas (1.86 ± 0.06 HO-1/β-actin) and
heart (1.37 ± 0.05 HO-1/β-actin) (Figure 1).betic +
D (n = 8)
Diabetic + pure
curcumin (n = 10)
Diabetic +
ZnPP (n = 8)
Diabetic + ZnPP +
NCD (n = 8)
*§ ± 21.2 192*§ ± 6.4 342*§ ± 25.5 217*§#• ± 20.5
*§ ± 0.22 0.71*§ ± 0.17 0.29*§ ± 0.12 0.60*#• ± 0.09
3*§ ± 0.7 11.0*§ ± 1.4 12.6* ± 1.3 11.8* ± 0.5
iabetic + NCD (p < 0.05).
Diabetic + ZnPP (p < 0.05).










curcumin (n = 10)
Diabetic +
ZnPP (n = 8)
Diabetic + ZnPP +
NCD (n = 8)
Pancreatic tissue 857.1 ± 156.6 1093* ± 153.7 1287.5* ± 204.8 1853.1*§ ± 208.1 1535 *§# ± 201.1 918.7§ ± 119.3 1390.6*# ± 110.1
Cardiac tissue 544.3 ± 63.0 739.5* ± 82.3 1060 * ± 90.5 1593.7* § ± 117.8 1206*§# ± 148.4 793.7*§ ± 125.8 1393.7* §#• ± 214.5
Results are presented as mean ± SD.
*Values differ significantly from control (p < 0.05). #Values differ significantly from Diabetic + NCD (p < 0.05).
§Values differ significantly from diabetic animals (p < 0.05). • Values differ significantly from Diabetic + ZnPP (p < 0.05).
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There was a significant increase (p < 0.001) in the mean
p300 gene expression level in the heart (0.85 ± 0.08
p300/β-actin) of diabetic rats compared with the control
group (0.24 ± 0.02 p300/β-actin). On the other hand
mean p300 gene expression level in the control group
(0.24 ± 0.02 p300/β-actin) showed no significant differ-
ence (p > 0.05) compared with the control group receiv-
ing the oral NCD (0.22 ± 0.04 p300/β-actin).
In addition, NCD supplementation to the diabetic rats
significantly decreased (p < 0.001) p300 gene expression
in the heart (0.48 ± 0.04 p300/β-actin) when compared
with the diabetic group (0.85 ± 0.08 p300/β-actin).
A significant decrease (p < 0.001) in the mean p300
gene expression level in the heart of the diabetic group
receiving pure curcumin (0.51 ± 0.07 p300/β-actin) com-
pared with the diabetic group (0.85 ± 0.08 p300/β-actin)
was detected. Whereas, it showed no significant differ-
ence (p > 0.05) compared with the diabetic group receiv-
ing the oral NCD (0.48 ± 0.04 p300/β-actin) (Figure 2).Results are presented as mean ± SD
Figure 1 Comparison between the heme oxygenase-1 gene expressio
differ significantly from control p < 0.001. §Values differ significantly from d
p < 0.001. • Values differ significantly from diabetic + inhibitor p < 0.001.Gene expression of molecular markers of cardiac
hypertrophy
There was a significant increase (p < 0.001) in the mean
ANP (0.68 ± 0.13 ANP/β-actin), MEF2A (2.52 ± 0.14
MEF2A/β-actin) and MEF2C (1.81 ± 0.12 MEF2C/β-
actin) gene expression levels in the heart of diabetic
rats compared to the corresponding control groups
(0.026 ±0.01ANP/β-actin), (0.18 ± 0.02 MEF2A/β-actin)
and (0.15 ± 0.01 MEF2C/β-actin), respectively.
On the other hand the mean ANP (0.024 ± 0.01 ANP/β-
actin), MEF2A (0.17 ± 0.02 MEF2A/β-actin) and MEF2C
(0.16 ± 0.01MEF2C/β-actin) gene expression levels in the
control groups receiving the NCD showed no significant
difference (p > 0.05) compared with the corresponding con-
trol groups (0.026 ±0.01ANP/β-actin), (0.18 ± 0.0 MEF2A/
β-actin) and (0.15 ± 0.01 MEF2C/β-actin), respectively.
In addition, NCD supplementation to the diabetic rats
significantly decreased (p < 0.001) the gene expression of
ANP (0.224 ± 0.09 ANP/β-actin), MEF2A (0.998 ± 0.09
MEF2A/β-actin), MEF2C (0.85 ± 0.09 MEF2C/β-actin)n of studied groups. Results are presented as mean ± SD. *Values
iabetic p < 0.001. #Values differ significantly from diabetic + NCD
Results are presented as mean ± SD
Figure 2 Comparison between the p300 gene expression of studied groups. Results are presented as mean ± SD. *Values differ significantly
from control p < 0.001. §Values differ significantly from diabetic p < 0.001. #Values differ significantly from diabetic + NCD p < 0.001. • Values differ
significantly from diabetic + inhibitor p < 0.001.
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(0.68 ± 0.13 ANP/β-actin), (2.52 ± 0.14 MEF2A/β-actin
and 1.81 ± 0.12 MEF2C/β-actin), respectively.
A significant decrease (p < 0.001) in the mean ANP
(0.249 ± 0.08 ANP/β-actin), MEF2A (1.03 ± 0.17 MEF2A/
β-actin) and MEF2C (0.99 ± 0.1 MEF2C/β-actin) the heart
of the diabetic group receiving pure curcumin comparedResults are presented as mean ± SD
Figure 3 Comparison between the gene expression of molecular mar
differ significantly from control p < 0.001. §Values differ significantly from d
p < 0.001. • Values differ significantly from diabetic + inhibitor p < 0.001.with the diabetic groups (0.68 ± 0.13 ANP/β-actin),
(2.52 ± 0.14 MEF2A/β-actin) and (1.81 ± 0.12 MEF2C/
β-actin), respectively was detected. Whereas, it showed
no significant difference (p > 0.05) compared with the
diabetic group receiving the oral NCD, (0.224 ± 0.09
ANP/β-actin), (0.99 ± 0.09 MEF2A/β-actin) and (0.85 ±
0.09 MEF2C/β-actin), respectively (Figure 3).kers of studied groups. Results are presented as mean ± SD. *Values
iabetic p < 0.001. #Values differ significantly from diabetic + NCD
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parameters
In the present study there was no significant difference
in the mean heart rate, SBP, LVDP and LV dp/dt in the
diabetic group receiving HO inhibitor ZnPP compared
with the diabetic group indicating the absence of any
effect of HO-1 on these parameters (Table 3).
In the diabetic group receiving the HO inhibitor ZnPP,
the mean plasma glucose level showed a significant in-
crease (p < 0.05), while the mean fasting plasma insulin
level showed a significant decrease (p < 0.05) compared
with the diabetic group (Table 4).
The mean plasma glucose level in the diabetic group
receiving the oral NCD combined with HO inhibitor
ZnPP showed a significant increase (p < 0.01), while the
mean fasting plasma insulin level showed a significant
decrease (p < 0.05) when compared with the diabetic
group receiving the oral water soluble curcumin deriva-
tive (Table 4).
In addition, administration of ZnPP to diabetic rats or
diabetic rats receiving NCD showed no significant differ-
ence (p > 005) in mean GHb level compared with the
diabetic group (Table 4).
Administration of ZnPP to diabetic rats significantly
decreased (p < 0.001) HO-activity (Table 5) and expres-
sion in the pancreas and heart (Figure 1) compared with
the corresponding diabetic groups.
Administration of ZnPP to diabetic rats or diabetic
rats receiving NCD showed no significant difference
(p > 0.05) in the mean p300 (Figure 2), and ANP,
MEF2A and MEF2C (Figure 3) gene expression levels
and in the heart of the diabetic group and the diabetic
group receiving oral NCD, respectively.
Discussion
Several studies reported that curcumin treatment
induced hypoglycemia in rats with STZ-induced DM
[23,24]. In the present study, administration of oral
NCD or pure curcumin to diabetic rats significantly
decreased blood glucose levels and increased the plasma
insulin compared with the diabetic group. However,
their levels did not reach those of normal controls. Dia-
betic rats receiving pure curcumin showed no significant
difference in the plasma glucose level compared with the
diabetic group receiving the NCD.
The results of the current study are in accordance with
the work of others who reported that administration of
oral curcumin to diabetic mice or rats fed with curcumin
resulted in a significant decrease in the blood glucose
level when compared with the diabetic group [25,26].
In the present work, oral NCD did not change the
plasma glucose levels in the control group while it
significantly increased the plasma insulin in the control
group. This agrees with another study [27] where theingestion of 6 g C. longa increased postprandial serum
insulin levels, but did not affect plasma glucose levels in
healthy subjects. Therefore, C. longa may have an effect
on insulin secretion. They pointed to the fact that in
healthy subjects, glucose levels are strictly regulated and it
is difficult to measure differences in plasma glucose levels.
Several mechanisms may explain how curcumin medi-
ates its hypoglycemic effects. Best et al. [28] reported
that curcumin activated the volume-regulated anion
channels in β-cells which was accompanied by the
depolarization of the cell membrane potential, the gener-
ation of electrical activity, and enhanced insulin secre-
tion. Another report indicated that curcumin treatment
enhances islet recovery by inducing heat-shock protein
Hsp70, a response protein, during cryopreservation [29]
so the activation of β-cells function by curcumin might
contribute to the hypoglycemic actions of this compound.
The current study agrees with the results of our previ-
ous work [6] on the effect of curcumin on insulin release
in rat isolated pancreatic islets. We reported that insulin
secretion was significantly increased in islets incuba-
ted with curcumin. Insulin secretion was significantly
decreased by incubation of islets with stannus meso-
porphyrin (HO activity inhibitor), indicating the role
of HO-1 in insulin secretion in pancreatic islets.
Additionally, curcumin was found to induce HO-1 ex-
pression, which has been reported to have cytoprotective
effects in mouse pancreatic beta-cells [5].
To determine whether curcumin’s action on blood glu-
cose and insulin was mediated via inducible HO-1, the
HO-1 inhibitor (ZnPP) was administered to diabetic rats
and diabetic rats receiving oral NCD. This resulted in a
significant increase in the plasma glucose level and a sig-
nificant decrease in insulin levels when compared with
the diabetic group receiving oral NCD only. Also, the
diabetic rats receiving ZnPP only demonstrated signifi-
cantly higher glucose levels and lower insulin levels
compared with the diabetic rats. This suggests that the
hypoglycemic action of curcumin may be, in part, medi-
ated through HO-1.
In the present work, there was a significant increase in
the mean GHb level in the diabetic group compared
with the controls. Diabetic rats supplemented with the
NCD or pure curcumin showed a modest but signifi-
cantly lower blood GHb level compared with the dia-
betic group. But, their levels were still higher than the
control group and no significant difference was detected
between diabetic rats receiving the oral NCD or pure
curcumin. Several studies are consistent with these re-
sults [30,31].
In the present study, there was a significant increase in
the mean HO-1 expression level and activity in the pan-
creatic and cardiac tissues of the diabetic group com-
pared with controls. The effect of diabetic conditions on
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various models in vitro and in vivo and the results of those
experiments are inconsistent [32,33]. However, even if
regulation of HO-1 expression in DM is still uncertain,
doubtlessly hyperglycemia leads to endothelial dysfunc-
tion, impaired cell replication and increased apoptosis [34]
and these effects are reversed by overexpression of anti-
oxidative enzymes, such as HO-1 [35]. DM caused up-
regulated expression of HO-1 in pancreatic β-cells of
ob/ob mice [36] and db/db mice [37], in liver [38] and
in glomerular cells of diabetic rats [32].
The present study showed that oral supplementation
of the NCD to control and diabetic rats, significantly in-
creased HO-1 expression and activity in the cardiac tis-
sue of the diabetic group compared with the controls. In
accordance with our results, HO mRNA, protein (both
isozymes) and activity was up-regulated in the heart of
diabetic rats [8].
Diabetic cardiomyopathy is characterized functionally
by ventricular dilation, myocyte hypertrophy, prominent
interstitial fibrosis and decreased or preserved systolic
function [39] in the presence of a diastolic dysfunction
[40]. In the present study, there was a significant de-
crease in the heart rate, LVDP, LV dp/dt and a significant
increase in systolic blood pressure in diabetic rats com-
pared with the control group.
The present results, agrees with the work of Radovits
et al. [41] and Riad et al. [42] who reported a significant
decrease in HR, LVDP and LV dp/dt in diabetic rats in-
dicating a decrease in cardiac contractility.
In diabetic rats receiving the NCD or pure curcumin,
left ventricular function was improved as indicated by
increased heart rate, LVDP, LV dp/dt and decreased sys-
tolic blood pressure when compared with diabetic rats.
This agrees with the results of Connelly et al. [43] who
reported that curcumin-treated diabetic rats demon-
strated reduced cardiac hypertrophy, improved chamber
compliance and enhanced systolic function when com-
pared with untreated diabetic counterparts.
In the present work, diabetic rats receiving pure
curcumin showed no significant difference compared
with the diabetic group receiving the NCD. Also, feeding
NCD did not affect these parameters in the control
group.
HO-1 is a very effective defensive system against
oxidative stress-induced cardiac cell damage [44] as well
as cardiac ischemia-reperfusion injury and organ rejec-
tion [45,46]. In addition, both CO and bilirubin, the 2
major products of heme degradation by HO, have been
demonstrated to exert a direct and significant protective
effect both in cardiac tissue [46] and during cold preser-
vation of organs [47].
Atrial and brain natriuretic peptides (ANP and BNP,
respectively) are polypeptide hormones comprising thecardiac-derived natriuretic peptide system [48,49]. ANP
is usually synthesized in the atria, while BNP is primarily
synthesized in the ventricles.
After birth, ventricular expression of both ANP and
BNP is upregulated in several pathological conditions of
the heart, and their plasma concentrations are markedly
elevated in patients with cardiac hypertrophy or congest-
ive heart failure (CHF) [50].
MEF2 is an important transcription factor in myocyte
hypertrophy [12]. MEF2 is associated with class II
HDACs. Translocation of HDAC to the cytoplasm frees
up MEF2, which allows for its association with HATs,
like p300, leading to the transcription of effector genes
[12,13]. MEF2 controls the expression of many fetal car-
diac genes. The normal adult heart has no MEF2-
dependent gene expression [51]. However, MEF2 gene
expression is activated in cardiac hypertrophy. Moreover,
blockade of MEF2-dependent gene expression com-
pletely inhibits cardiac hypertrophy caused by a variety
of prohypertrophic stimuli [52].
In the present study, ANP, MEF2A and MEF2C (mo-
lecular markers of cardiac hypertrophy) gene expressions
were significantly higher in the diabetic group compared
with the controls. However, in diabetic rats receiving
NCD or pure curcumin the gene expression of ANP,
MEF2A and MEF2C was significantly lower than the
diabetic group. In addition, the p300 gene expression
showed similar results.
Our results agree with several studies that reported
that the expression and secretion of ANP and BNP is
up-regulated in diseased hearts such as those showing
cardiac hypertrophy or cardiomyopathy, and mechanical
stress stimulates the synthesis and secretion of ANP and
BNP in both atrial and ventricular cells [53,54].
The results of the current study are in accordance with
the work of Feng et al. [55] who reported that treatment
with p300 blocker, curcumin prevented diabetes-induced
upregulation of these transcripts suggesting the existence
in curcumin of a novel glucose-induced epigenetic mech-
anism regulating gene expression and cardiomyocyte
hypertrophy in DM.
The increase in p300 gene expression in hearts of dia-
betic rats may be due to hyperglycemia. Several signaling
mechanisms activated by hyperglycemia may stimulate
the activation of p300 [55]. It was previously demon-
strated that, in endothelial cells, hyperglycemia-induced
protein kinase C and mitogen-activated protein kinase,
as well as protein kinase B activation, may enhance the
activity of p300 [56]. All such pathways have been dem-
onstrated in the heart of diabetic animals and may po-
tentially contribute to p300 activation [57,58]. These
studies support the notion that p300 may represent a
common final pathway upon which several signaling
mechanisms may converge.
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nificant difference in ANP, MEF2A, MEF2C and p300
gene expression compared with diabetic group receiving
the NCD. Also, feeding NCD did not affect these param-
eters in the control group.
In the present study, to determine whether inducible
HO-1 in the heart contributes to the inhibitory effect of
curcumin, ZnPP (HO -1 inhibitor) was administered to
the diabetic rats. No significant difference was detected
in physiological parameters compared with the diabetic
group. Similarly, no significant difference in p300 gene
expression was detected in cardiac tissues compared
with the diabetic group. Also, there was no significant
difference was detected in p300 gene expression in the
diabetic group receiving the NCD when compared
with the diabetic group receiving NCD combined with
HO inhibitor ZnPP. Thus, curcumin decreased the
p300 gene expression in cardiac tissue by a direct
effect rather than induction of HO-1. In addition, ANP,
MEF2A and MEF2C gene expressions showed similar
results.
In the present study, there was no significant difference
between administration of NCD and pure curcumin.
However, the effect of NCD by its small dose (20 mg/Kg/
day orally for 45 days) taking into consideration that the
novel curcumin derivative has only a 3.0% curcumin con-
tent, gave the same results as pure curcumin (20 mg/Kg/
day orally for 45 days). Thus, NCD was absorbed at a
higher rate than pure curcumin and NCD still retains the
essential potencies of natural curcumin.
In conclusion, NCD and curcumin decreased plasma
glucose, GHb and increased insulin levels significantly in
diabetic rats and its action may be partially mediated by
induction of HO-1. HO-1 gene expression and HO
activity were significantly increased in diabetic heart and
pancreas. Diabetes upregulated expression of cardiomy-
opathy markers and p300. However, NCD and curcumin
prevented DM-induced upregulation of these parameters
and improved left ventricular function. The effect of the
NCD was better than the same dose of curcumin.Competing interests
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